20

25

30





WHAT IS CLAIMED IS:

- 1. A substantially pure or recombinant 312C2 protein or conservatively modified variants thereof, said protein:
 - a) is expressed on activated T cells; or
 - b) specifically binds to antibodies generated against SEQ ID NO: 2 or 4.
- 2. A protein or peptide of Claim 1, selected from the group consisting of:
 - a) a natural protein from a warm blooded animal selected from the group of birds and mammals, including a rodent or primate;
- b) a protein or pertide:
 - i) comprising at least one polypeptide segment of at least 14 amino acids of SEQ ID NO: 2;
 - ii) comprising at least one polypeptide segment of at least 14 amino acids of SEQ ID NO: 4; or
 - iii) which is not glycosylated;
 - iv) which fs in a buffered solution;
 - v) which i/s attached to a solid substrate;
 - vi) which exhibits a plurality of epitopes from SEQ ID NO: 2 or 4;
 - vii) which is detectably labeled;
 - viii) which is a synthetic polypeptide;
 - ix) which is conjugated to a chemical moiety;
 - x) which is a 5-fold or less substitution from a natural sequence; or
 - which is a deletion or insertion variant from a natural sequence.
- 3. A protein or peptide of Claim 1, comprising a sequence from the extracellular or the intracellular portion of a 312C2.

76

5



- 4. A fusion protein comprising a peptide of Claim 1.
- 5. A sterile composition comprising the protein of Claim 1, and a pharmaceutically acceptable carrier.
- 6. An antibody which specifically binds a protein or peptide of Claim 1.
- 7. An antibody of Claim 6, wherein:
- a) said 312C2 is a mammalian protein, including a mouse or human;
 - b) said antibody raised against a purified peptide sequence of SEQ ID NO: 2 or 4;
 - c) said antibody is a monoclonal antibody;
- d) said antibody is detectably labeled;
 - e) said antibody is attached to a solid substrate;
 - f) said antibody is in a sterile composition; or
 - g) said antibody is in a buffered composition.
- 20 8. A method of purifying a 312C2 protein or peptide from other materials in a mixture comprising contacting said mixture to an antibody of Claim 6, and separating bound 312C2 from other materials.
 - 9. An isolated or recombinant nucleic acid capable of encoding a protein or peptide of Claim 1.
 - 10. A nucleic acid of Claim 9, wherein said nucleic acid:
 - a) encodes a sequence of SEQ ID NO: 2 or 4;
 - b) comprises a sequence of SEQ ID NO: 1 or 3; or
 - c) encodes a sequence from an extracellular domain of a natural 312C2;
 - d) encodes a sequence from an intracellular domain of a natural 312C2;
 - e) attached to a solid substrate;
 - f) is detectable labeled; or
 - g) Is in a sterile composition.

30

35

N

5

20

25





- An expression or replicating vector of Claim 9. 11.
- 12. A kit comprising:
 - a substantially pure 312C2 or fragment of Claim 1;
 - an antibody or receptor which specifically binds a 312C2; or
 - a nucleic/acid encoding a 312C2 or peptide.
- A method for detecting ψ n a sample the presence of a 10 312C2 nucleic acid, protein, or antibody, comprising testing said sample with a kit of Claim 12.
- A method of modulating the physiology of a cell 14. comprising contacting said cell with: 15
 - a substantially pure 312C2 or fragment of Claim 1;
 - an antibody \sqrt{r} binding partner which specifically b) binds a 312CX or
 - a nucleic acid/encoding a 312C2 or peptide.

The method of Claim 14, wherein said cell is a T cell and said modulating of physiology is:

- apoptosis of said T cell; or
- activation of said T cell b)
- A method of Claim 14, wherein said cell is in a tissue and/or in an organism.
- A method of expressing a 312C2 comprising expressing a nucleic acid of Clafim 9.
- A cell, tissue, organ, or organism comprising a nucleic acid of/Claim 9.
- A recombinant nucleic acid comprising sequence at 35 19. least about #0% identity over a stretch of at least about

chron a chron

30 nucleotides to a 312C2/nucleic acid sequence of SEQ ID NO: 1 or 3.

- 20. A nucleic acid of Claim 19, further encoding a polypeptide comprising at least about 60% identity over a stretch of at least about 20 amino acids to a 312C2 sequence of SEQ ID NO: 2 or 4.
- 21. A method of treating a host mammal having an abnormal immune response by administering to said mammal an effective dose of:
 - a) an antibody or binding partner which binds specifically/to a 312C2;
 - b) a substantially pure 312C2 protein or peptide thereof; or/
 - c) a nucleic affid encoding a 312C2 peptide.
 - 22. The method of Claim 21, wherein said abnormal immune response is characterized by:
 - a) a T-cel/1 immune deficiency;
 - b) chronic inflammation; or
 - c) tissue rejection.

20

15

add

900